HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors

Starting soon

Conditions studied: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia, Pediatric

In brief

This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late effects. The study hypothesizes that a standardized follow-up path managed by an electronic platform will improve follow-up compliance and reduce the missed diagnosis rate of late effects.

Key facts

Study ID

NCT07483749

Run by

The Children's Hospital of Zhejiang University School of Medicine

People needed

400

Starts

2026-03-25

Expected to finish

2028-12-01

Last updated by the study team

2026-03-19

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.
• Age 1-21 years.
• Capable of completing follow-up and data collection.
• Informed consent signed.

You may not qualify if…

• Severe organ failure preventing follow-up.
• Major genetic or systemic diseases affecting growth/organ function.
• Expected poor compliance or refusal to participate.

Where it is running

• Children's hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
• Hangzhou Children's Hospital — Hangzhou, Zhejiang, China
• Affiliated Women and Children's Hospital of Ningbo University — Ningbo, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.